Recombinant Human CCL22
Catalog No : IGX-RP586
788.99€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human CCL22 | ||
|---|---|---|---|
| Catalog No | IGX-RP586 | ||
| Supplier’s Catalog No | IGX-RP586 | ||
| Supplier | ImuGeX | ||
| Source antigen | E. coli | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 8 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | STCP-1, ABCD-1, CCL22, CC chemokine STCP-1, MDC(1-69), SCYA22, Small-inducible cytokine A22, Stimulated T-cell chemotactic protein 1, MDC, C-C motif chemokine 22 <br/>Recombinant Human Macrophage-Derived Chemokine (CCL22) | ||
| Grade | Highly Purified | ||
| Purity | >95% as determined by SDS-PAGE | ||
| Form | Lyophilized from 0.2 μm filtered solution in Tris and NaCl, pH 7.0. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | >95% as determined by SDS-PAGE | ||
| Description | CCL22 (monocyte-derived chemokine) was described initially as a constitutively produced, thymus-specific chemokine, implicated in the recruitment of T cells . One of the functions of CCL22 originally described was induction of migration of CCR4+ Th2 cells, but it has additionally been shown to regulate migration of Tregs. CCL22 has been implicated in a number of diseases, including allergen-induced lung inflammation, atopic dermatitis, and lymphoma. Similarly, a presumed role for CCR4+ cells has been suggested for endotoxic shock, rheumatoid arthritis, T cell lymphoma, and autoimmune diabetes | ||
Product Details
© 2020 Imugex All Rights Reserved